VRTX
$499.74-1.77%
as of close, Oct 16, 2026
☾ AH $499.74 -1.77%
Vertex Pharmaceuticals IncorporatedStock · HealthcareNasdaq-100 0.5%Nasdaq Composite 0.2%S&P 500 Equal Weight 0.2%S&P 500 0.2%Russell 1000 0.2%Russell 3000 0.2%US Stock Market 0.2%MSCI World 0.1%MSCI ACWI 0.1%
VRTX SEC filings (2026)
CIK 875320 · Pharmaceutical Preparations (SIC 2834) · incorporated in MA · fiscal year ends in December
3,634 filings on EDGAR since 1995 · 31 annual, 98 quarterly, 293 current · financial statements · earnings
Latest 10-K
Feb 13, 2026
fiscal year to Dec 31, 2025
Latest 10-Q
Aug 4, 2026
quarter to Jun 30, 2026
Latest 8-K
Sep 1, 2026
Directors or officers; compensation
Last earnings release
Aug 3, 2026
$4.20 vs $4.15 · ▲ 1.7%
Filings on file
3,634
since 1995, 2,745 insider forms
What happened, last 12 months#
Every earnings release with its print, every report with its quarter, the other 8-Ks by the headline of the press release they furnish or by their items, the proxy statements, and each day an insider bought or sold — newest first, each line opening the filing on EDGAR. The index by form and year follows.
September 2026
- Sep 18-K8-K · Directors or officers; compensation
August 2026
July 2026
- Jul 78-K8-K · Material definitive agreement; Regulation FD disclosure; Other events
- Jul 2Insider saleMcKechnie Duncan (EVP, Chief Commercial Officer) sold 1,541 shares for $800K at $519.00 under a 10b5-1 plan
- Jul 2Insider saleTatsis Ourania (EVP, Chief Reg. & Quality Off.) sold 1,500 shares for $787K at $524.99 under a 10b5-1 plan
- Jul 1Insider saleLiu Joy (EVP and Chief Legal Officer) sold 828 shares for $416K at $502.71 under a 10b5-1 plan
June 2026
- Jun 26Insider saleBozic Carmen (EVP and CMO) sold 596 shares for $288K at $482.50 under a 10b5-1 plan
- Jun 18Insider saleBozic Carmen (EVP and CMO) sold 1,020 shares for $471K at $462.17 under a 10b5-1 plan
- Jun 15Insider saleBozic Carmen (EVP and CMO) sold 4,062 shares for $1.8M at $450.00 under a 10b5-1 plan
- Jun 5Insider saleBozic Carmen (EVP and CMO) sold 1,745 shares for $785K at $450.00 under a 10b5-1 plan
- Jun 1Insider saleLiu Joy (EVP and Chief Legal Officer) sold 828 shares for $364K at $439.91 under a 10b5-1 plan
May 2026
- May 29Insider saleBozic Carmen (EVP and CMO) sold 1,974 shares for $888K at $450.00 under a 10b5-1 plan
- May 15Insider saleBozic Carmen (EVP and CMO) sold 1,354 shares for $614K at $453.45 under a 10b5-1 plan
- May 15Insider saleBunnage Mark E. (EVP, Chief Scientific Officer) sold 33 shares for $15K at $453.45 under a 10b5-1 plan
- May 138-K8-K · Directors or officers; compensation; Shareholder vote results
- May 12Insider saleBozic Carmen (EVP and CMO) sold 6,988 shares for $3.1M at $450.00 under a 10b5-1 plan
- May 5ReportQuarterly report, Q1 2026 — revenue $2.99B (+8% y/y), net income $1.03B, EPS $4.02
- May 4EarningsEarnings release — EPS $3.95 vs $3.69 est. (+7.0%); revenue $2.99B (+8% y/y) 1.3%
- May 4Insider saleBhatia Sangeeta N. (Director) sold 318 shares for $135K at $423.73 under a 10b5-1 plan
- May 1Insider saleLiu Joy (EVP and Chief Legal Officer) sold 1,104 shares for $469K at $425.02 under a 10b5-1 plan
April 2026
- Apr 298-K8-K · Directors or officers; compensation
- Apr 29ProxyProxy · Additional proxy materials
- Apr 2ProxyProxy · Annual report to shareholders
- Apr 2ProxyProxy · Additional proxy materials
- Apr 2ProxyProxy · Proxy statement
- Apr 1Insider saleLiu Joy (EVP and Chief Legal Officer) sold 978 shares for $439K at $449.17 under a 10b5-1 plan
March 2026
- Mar 318-K8-K · Other events
- Mar 27Insider saleBozic Carmen (EVP and CMO) sold 2,329 shares for $1.1M at $450.95 under a 10b5-1 plan
- Mar 13Insider saleBozic Carmen (EVP and CMO) sold 2,329 shares for $1.1M at $481.79 under a 10b5-1 plan
- Mar 11Insider saleMcKechnie Duncan (EVP, Chief Commercial Officer) sold 2,633 shares for $1.3M at $498.42 under a 10b5-1 plan
- Mar 4Insider saleMcKechnie Duncan (EVP, Chief Commercial Officer) sold 2,437 shares for $1.2M at $475.30 under a 10b5-1 plan
- Mar 2Insider saleLiu Joy (EVP and Chief Legal Officer) sold 892 shares for $442K at $495.96 under a 10b5-1 plan
February 2026
- Feb 27Insider saleKewalramani Reshma (CEO & President · Director) sold 40,000 shares for $19.7M at $479.75–$496.95 under a 10b5-1 plan
- Feb 27Insider saleBozic Carmen (EVP and CMO) sold 2,329 shares for $1.1M at $480.31 under a 10b5-1 plan
- Feb 26Insider saleAmbrose Kristen (SVP & Chief Accounting Officer) sold 357 shares for $173K at $483.36 under a 10b5-1 plan
- Feb 25Insider saleMcKechnie Duncan (EVP, Chief Commercial Officer) sold 4,910 shares for $2.4M at $486.35–$489.00 under a 10b5-1 plan
- Feb 25Insider saleSachdev Amit (EVP Chief Patient & Ext Af Off) sold 1,846 shares for $898K at $486.35 under a 10b5-1 plan
- Feb 25Insider saleBiller Jonathan (EVP and Chief Legal Officer) sold 945 shares for $460K at $486.35 under a 10b5-1 plan
- Feb 25Insider saleAtkinson Edward Morrow III (EVP, Chief Technical Ops. Off.) sold 668 shares for $325K at $486.35 under a 10b5-1 plan
- Feb 25Insider saleBunnage Mark E. (EVP, Chief Scientific Officer) sold 620 shares for $302K at $486.35 under a 10b5-1 plan
- Feb 25Insider saleTatsis Ourania (EVP, Chief Reg. & Quality Off.) sold 260 shares for $126K at $486.35 under a 10b5-1 plan
- Feb 25Insider saleAmbrose Kristen (SVP & Chief Accounting Officer) sold 223 shares for $108K at $486.35 under a 10b5-1 plan
- Feb 19Insider saleSachdev Amit (EVP Chief Patient & Ext Af Off) sold 58,613 shares for $27.5M at $463.91–$471.43 under a 10b5-1 plan
- Feb 18Insider saleBiller Jonathan (EVP and Chief Legal Officer) sold 1,244 shares for $589K at $473.68 under a 10b5-1 plan
- Feb 18Insider saleBunnage Mark E. (EVP, Chief Scientific Officer) sold 1,182 shares for $560K at $473.68 under a 10b5-1 plan
- Feb 18Insider saleAtkinson Edward Morrow III (EVP, Chief Technical Ops. Off.) sold 817 shares for $387K at $473.68 under a 10b5-1 plan
- Feb 18Insider saleAmbrose Kristen (SVP & Chief Accounting Officer) sold 638 shares for $302K at $473.68 under a 10b5-1 plan
- Feb 18Insider saleTatsis Ourania (EVP, Chief Reg. & Quality Off.) sold 368 shares for $174K at $473.68 under a 10b5-1 plan
- Feb 17Insider saleBiller Jonathan (EVP and Chief Legal Officer) sold 2,476 shares for $1.2M at $489.46 under a 10b5-1 plan
- Feb 17Insider saleBunnage Mark E. (EVP, Chief Scientific Officer) sold 2,437 shares for $1.2M at $489.46 under a 10b5-1 plan
- Feb 17Insider saleAtkinson Edward Morrow III (EVP, Chief Technical Ops. Off.) sold 2,031 shares for $994K at $489.46 under a 10b5-1 plan
- Feb 17Insider saleAmbrose Kristen (SVP & Chief Accounting Officer) sold 1,557 shares for $762K at $489.46 under a 10b5-1 plan
- Feb 17Insider saleTatsis Ourania (EVP, Chief Reg. & Quality Off.) sold 609 shares for $298K at $489.46 under a 10b5-1 plan
- Feb 13ReportAnnual report, FY2025 — revenue $12.00B (+9% y/y), net income $3.95B, EPS $15.32
- Feb 13Insider saleTatsis Ourania (EVP, Chief Reg. & Quality Off.) sold 1,500 shares for $750K at $499.99 under a 10b5-1 plan
- Feb 13Insider saleBiller Jonathan (EVP and Chief Legal Officer) sold 988 shares for $493K at $499.00 under a 10b5-1 plan
- Feb 13Insider saleBhatia Sangeeta N. (Director) sold 266 shares for $133K at $500.00 under a 10b5-1 plan
- Feb 12EarningsEarnings release — EPS $4.65 vs $4.40 est. (+5.7%); revenue $3.19B (+10% y/y) 5.7%
- Feb 11Insider saleBunnage Mark E. (EVP, Chief Scientific Officer) sold 2,021 shares for $931K at $460.43 under a 10b5-1 plan
- Feb 11Insider saleBiller Jonathan (EVP and Chief Legal Officer) sold 1,925 shares for $886K at $460.43 under a 10b5-1 plan
- Feb 11Insider saleAtkinson Edward Morrow III (EVP, Chief Technical Ops. Off.) sold 1,751 shares for $806K at $460.43 under a 10b5-1 plan
- Feb 11Insider saleAmbrose Kristen (SVP & Chief Accounting Officer) sold 1,376 shares for $634K at $460.43 under a 10b5-1 plan
- Feb 11Insider saleTatsis Ourania (EVP, Chief Reg. & Quality Off.) sold 466 shares for $215K at $460.43 under a 10b5-1 plan
January 2026
November 2025
Insider transactions#
What officers, directors and 10% holders reported on Forms 4 and 5 over the last 13 months, from the documents themselves: one insider’s trades of one kind on one day are one row, with the shares, the price range and the total as filed. Open-market buys and sells first; awards, exercises, tax withholding, gifts and employee-plan purchases are grouped below them.
Over the last 13 months insiders sold $87.5M in 51 sales and bought nothing on the open market; 100 other transactions (awards, exercises, tax withholding, gifts and plan purchases).
| Date | Insider |
|---|---|
| Jul 2, 2026Form 4 | McKechnie DuncanEVP, Chief Commercial OfficerSold · $800K · 1,541 sh · 10b5-1 |
| Jul 2, 2026Form 4 | Tatsis OuraniaEVP, Chief Reg. & Quality Off.Sold · $787K · 1,500 sh · 10b5-1 |
| Jul 1, 2026Form 4 | Liu JoyEVP and Chief Legal OfficerSold · $416K · 828 sh · 10b5-1 |
| Jun 26, 2026Form 4 | Bozic CarmenEVP and CMOSold · $288K · 596 sh · 10b5-1 |
| Jun 18, 2026Form 4 | Bozic CarmenEVP and CMOSold · $471K · 1,020 sh · 10b5-1 |
| Jun 15, 2026Form 4 | Bozic CarmenEVP and CMOSold · $1.8M · 4,062 sh · 10b5-1 |
| Jun 5, 2026Form 4 | Bozic CarmenEVP and CMOSold · $785K · 1,745 sh · 10b5-1 |
| Jun 1, 2026Form 4 | Liu JoyEVP and Chief Legal OfficerSold · $364K · 828 sh · 10b5-1 |
| May 29, 2026Form 4 | Bozic CarmenEVP and CMOSold · $888K · 1,974 sh · 10b5-1 |
| May 15, 2026Form 4 | Bozic CarmenEVP and CMOSold · $614K · 1,354 sh · 10b5-1 |
| May 15, 2026Form 4 | Bunnage Mark E.EVP, Chief Scientific OfficerSold · $15K · 33 sh · 10b5-1 |
| May 12, 2026Form 4 | Bozic CarmenEVP and CMOSold · $3.1M · 6,988 sh · 10b5-1 |
| May 4, 2026Form 4 | Bhatia Sangeeta N.DirectorSold · $135K · 318 sh · 10b5-1 |
| May 1, 2026Form 4 | Liu JoyEVP and Chief Legal OfficerSold · $469K · 1,104 sh · 10b5-1 |
| Apr 1, 2026Form 4 | Liu JoyEVP and Chief Legal OfficerSold · $439K · 978 sh · 10b5-1 |
| Mar 27, 2026Form 4 | Bozic CarmenEVP and CMOSold · $1.1M · 2,329 sh · 10b5-1 |
| Mar 13, 2026Form 4 | Bozic CarmenEVP and CMOSold · $1.1M · 2,329 sh · 10b5-1 |
| Mar 11, 2026Form 4 | McKechnie DuncanEVP, Chief Commercial OfficerSold · $1.3M · 2,633 sh · 10b5-1 |
| Mar 4, 2026Form 4 | McKechnie DuncanEVP, Chief Commercial OfficerSold · $1.2M · 2,437 sh · 10b5-1 |
| Mar 2, 2026Form 4 | Liu JoyEVP and Chief Legal OfficerSold · $442K · 892 sh · 10b5-1 |
| Feb 27, 2026Form 4 | Kewalramani ReshmaCEO & President · DirectorSold · $19.7M · 40,000 sh · 10b5-1 |
| Feb 27, 2026Form 4 | Bozic CarmenEVP and CMOSold · $1.1M · 2,329 sh · 10b5-1 |
| Feb 26, 2026Form 4 | Ambrose KristenSVP & Chief Accounting OfficerSold · $173K · 357 sh · 10b5-1 |
| Feb 25, 2026Form 4 | McKechnie DuncanEVP, Chief Commercial OfficerSold · $2.4M · 4,910 sh · 10b5-1 |
| Feb 25, 2026Form 4 | Sachdev AmitEVP Chief Patient & Ext Af OffSold · $898K · 1,846 sh · 10b5-1 |
| Feb 25, 2026Form 4 | Biller JonathanEVP and Chief Legal OfficerSold · $460K · 945 sh · 10b5-1 |
| Feb 25, 2026Form 4 | Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off.Sold · $325K · 668 sh · 10b5-1 |
| Feb 25, 2026Form 4 | Bunnage Mark E.EVP, Chief Scientific OfficerSold · $302K · 620 sh · 10b5-1 |
| Feb 25, 2026Form 4 | Tatsis OuraniaEVP, Chief Reg. & Quality Off.Sold · $126K · 260 sh · 10b5-1 |
| Feb 25, 2026Form 4 | Ambrose KristenSVP & Chief Accounting OfficerSold · $108K · 223 sh · 10b5-1 |
| Feb 19, 2026Form 4 | Sachdev AmitEVP Chief Patient & Ext Af OffSold · $27.5M · 58,613 sh · 10b5-1 |
| Feb 18, 2026Form 4 | Biller JonathanEVP and Chief Legal OfficerSold · $589K · 1,244 sh · 10b5-1 |
| Feb 18, 2026Form 4 | Bunnage Mark E.EVP, Chief Scientific OfficerSold · $560K · 1,182 sh · 10b5-1 |
| Feb 18, 2026Form 4 | Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off.Sold · $387K · 817 sh · 10b5-1 |
| Feb 18, 2026Form 4 | Ambrose KristenSVP & Chief Accounting OfficerSold · $302K · 638 sh · 10b5-1 |
| Feb 18, 2026Form 4 | Tatsis OuraniaEVP, Chief Reg. & Quality Off.Sold · $174K · 368 sh · 10b5-1 |
| Feb 17, 2026Form 4 | Biller JonathanEVP and Chief Legal OfficerSold · $1.2M · 2,476 sh · 10b5-1 |
| Feb 17, 2026Form 4 | Bunnage Mark E.EVP, Chief Scientific OfficerSold · $1.2M · 2,437 sh · 10b5-1 |
| Feb 17, 2026Form 4 | Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off.Sold · $994K · 2,031 sh · 10b5-1 |
| Feb 17, 2026Form 4 | Ambrose KristenSVP & Chief Accounting OfficerSold · $762K · 1,557 sh · 10b5-1 |
| Feb 17, 2026Form 4 | Tatsis OuraniaEVP, Chief Reg. & Quality Off.Sold · $298K · 609 sh · 10b5-1 |
| Feb 13, 2026Form 4 | Tatsis OuraniaEVP, Chief Reg. & Quality Off.Sold · $750K · 1,500 sh · 10b5-1 |
| Feb 13, 2026Form 4 | Biller JonathanEVP and Chief Legal OfficerSold · $493K · 988 sh · 10b5-1 |
| Feb 13, 2026Form 4 | Bhatia Sangeeta N.DirectorSold · $133K · 266 sh · 10b5-1 |
| Feb 11, 2026Form 4 | Bunnage Mark E.EVP, Chief Scientific OfficerSold · $931K · 2,021 sh · 10b5-1 |
| Feb 11, 2026Form 4 | Biller JonathanEVP and Chief Legal OfficerSold · $886K · 1,925 sh · 10b5-1 |
| Feb 11, 2026Form 4 | Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off.Sold · $806K · 1,751 sh · 10b5-1 |
| Feb 11, 2026Form 4 | Ambrose KristenSVP & Chief Accounting OfficerSold · $634K · 1,376 sh · 10b5-1 |
| Feb 11, 2026Form 4 | Tatsis OuraniaEVP, Chief Reg. & Quality Off.Sold · $215K · 466 sh · 10b5-1 |
| Jan 7, 2026Form 4 | Tatsis OuraniaEVP, Chief Reg. & Quality Off.Sold · $2.1M · 4,500 sh · 10b5-1 |
| Jan 6, 2026Form 4 | WAGNER CHARLES F JREVP, CO & FOSold · $4.4M · 9,532 sh · 10b5-1 |
Awards, exercises, withholding and plan purchases · 100 transactions
| Date | Insider |
|---|---|
| Sep 8, 2026Form 4 | van Grunsven JasperEVP, CP and NPPOAward · $0 · 8,682 sh |
| Aug 28, 2026Form 4 | Ambrose KristenSVP & Chief Accounting OfficerAward · $0 · 5,000 sh |
| Aug 27, 2026Form 4 | SACHS BRUCE IDirectorGift · $0 · 6,000 sh |
| Jul 21, 2026Form 4 | Sachdev AmitEVP Chief Patient & Ext Af OffAward · $0 · 8,251 sh |
| Jul 21, 2026Form 4 | Tatsis OuraniaEVP, Chief Reg. & Quality Off.Award · $0 · 8,251 sh |
| Jul 15, 2026Form 4 | SACHS BRUCE IDirectorAward · Deferred Stock Units · $47K · 99.941 sh |
| Jul 15, 2026Form 4 | Garber Alan MDirectorAward · Deferred Stock Units · $15K · 31.56 sh |
| May 1, 2026Form 4 | CARNEY LLOYDDirectorAward · Stock Option (Right to Buy) · $0 · 2,866 sh |
| May 1, 2026Form 4 | Lagarde MichelDirectorAward · Stock Option (Right to Buy) · $0 · 2,866 sh |
| May 1, 2026Form 4 | SACHS BRUCE IDirectorAward · Stock Option (Right to Buy) · $0 · 2,866 sh |
| May 1, 2026Form 4 | Upadhyay SuketuDirectorAward · Stock Option (Right to Buy) · $0 · 2,866 sh |
| May 1, 2026Form 4 | Garber Alan MDirectorAward · Stock Option (Right to Buy) · $0 · 1,433 sh |
| May 1, 2026Form 4 | Schneider JenniferDirectorAward · Stock Option (Right to Buy) · $0 · 1,433 sh |
| May 1, 2026Form 4 | Thornberry NancyDirectorAward · Stock Option (Right to Buy) · $0 · 1,433 sh |
| May 1, 2026Form 4 | Bhatia Sangeeta N.DirectorAward · $0 · 943 sh · 10b5-1 |
| May 1, 2026Form 4 | MCKENZIE DIANADirectorAward · $0 · 943 sh |
| May 1, 2026Form 4 | MCKENZIE DIANADirectorOther · — · 796 sh |
| May 1, 2026Form 4 | MCKENZIE DIANADirectorAward · Deferred Stock Units · — · 796 sh |
| May 1, 2026Form 4 | Schneider JenniferDirectorOther · — · 796 sh |
| May 1, 2026Form 4 | Schneider JenniferDirectorAward · Deferred Stock Units · — · 796 sh |
| May 1, 2026Form 4 | Upadhyay SuketuDirectorOther · — · 796 sh |
| May 1, 2026Form 4 | Upadhyay SuketuDirectorAward · Deferred Stock Units · — · 796 sh |
| May 1, 2026Form 4 | Garber Alan MDirectorAward · $0 · 472 sh |
| May 1, 2026Form 4 | Schneider JenniferDirectorAward · $0 · 472 sh |
| May 1, 2026Form 4 | Thornberry NancyDirectorAward · $0 · 472 sh |
| May 1, 2026Form 4 | Thornberry NancyDirectorOther · — · 398 sh |
| May 1, 2026Form 4 | Thornberry NancyDirectorAward · Deferred Stock Units · — · 398 sh |
| Apr 15, 2026Form 4 | SACHS BRUCE IDirectorAward · Deferred Stock Units · $48K · 107.345 sh |
| Apr 15, 2026Form 4 | Upadhyay SuketuDirectorAward · Deferred Stock Units · $36K · 80.508 sh |
| Apr 15, 2026Form 4 | Garber Alan MDirectorAward · Deferred Stock Units · $15K · 33.898 sh |
| Feb 24, 2026Form 4 | Kewalramani ReshmaCEO & President · DirectorTax withholding · $2.4M · 4,981 sh |
| Feb 24, 2026Form 4 | LEIDEN JEFFREY MExecutive Chairman · DirectorTax withholding · $1.7M · 3,547 sh |
| Feb 24, 2026Form 4 | WAGNER CHARLES F JREVP, CO & FOTax withholding · $846K · 1,744 sh |
| Feb 24, 2026Form 4 | Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off.Tax withholding · $789K · 1,627 sh · 10b5-1 |
| Feb 24, 2026Form 4 | Tatsis OuraniaEVP, Chief Reg. & Quality Off.Tax withholding · $789K · 1,627 sh · 10b5-1 |
| Feb 24, 2026Form 4 | Sachdev AmitEVP Chief Patient & Ext Af OffTax withholding · $736K · 1,518 sh · 10b5-1 |
| Feb 24, 2026Form 4 | Bozic CarmenEVP and CMOTax withholding · $705K · 1,453 sh |
| Feb 24, 2026Form 4 | Biller JonathanEVP and Chief Legal OfficerTax withholding · $555K · 1,144 sh · 10b5-1 |
| Feb 24, 2026Form 4 | McKechnie DuncanEVP, Chief Commercial OfficerTax withholding · $424K · 873 sh · 10b5-1 |
| Feb 24, 2026Form 4 | Bunnage Mark E.EVP, Chief Scientific OfficerTax withholding · $282K · 582 sh · 10b5-1 |
| Feb 24, 2026Form 4 | Ambrose KristenSVP & Chief Accounting OfficerTax withholding · $265K · 546 sh · 10b5-1 |
| Feb 19, 2026Form 4 | Sachdev AmitEVP Chief Patient & Ext Af OffExercise or conversion · $8.3M · 48,505 sh · 10b5-1 |
| Feb 19, 2026Form 4 | Sachdev AmitEVP Chief Patient & Ext Af OffExercise or conversion · Stock Option (Right to Buy) · $0 · 48,505 sh · 10b5-1 |
| Feb 18, 2026Form 4 | LEIDEN JEFFREY MExecutive Chairman · DirectorTax withholding · $1.4M · 2,964 sh |
| Feb 17, 2026Form 4 | Kewalramani ReshmaCEO & President · DirectorTax withholding · $3.2M · 6,554 sh |
| Feb 17, 2026Form 4 | Tatsis OuraniaEVP, Chief Reg. & Quality Off.Tax withholding · $1.1M · 2,294 sh · 10b5-1 |
| Feb 17, 2026Form 4 | WAGNER CHARLES F JREVP, CO & FOTax withholding · $1.1M · 2,294 sh |
| Feb 17, 2026Form 4 | Sachdev AmitEVP Chief Patient & Ext Af OffTax withholding · $1.0M · 2,140 sh |
| Feb 17, 2026Form 4 | Bozic CarmenEVP and CMOTax withholding · $925K · 1,912 sh |
| Feb 17, 2026Form 4 | Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off.Tax withholding · $740K · 1,530 sh · 10b5-1 |
| Feb 17, 2026Form 4 | Biller JonathanEVP and Chief Legal OfficerTax withholding · $728K · 1,505 sh · 10b5-1 |
| Feb 17, 2026Form 4 | McKechnie DuncanEVP, Chief Commercial OfficerTax withholding · $555K · 1,148 sh |
| Feb 17, 2026Form 4 | Bunnage Mark E.EVP, Chief Scientific OfficerTax withholding · $537K · 1,110 sh · 10b5-1 |
| Feb 17, 2026Form 4 | Ambrose KristenSVP & Chief Accounting OfficerTax withholding · $289K · 598 sh · 10b5-1 |
| Feb 17, 2026Form 4 | Kewalramani ReshmaCEO & President · DirectorAward · $0 · 16,326 sh |
| Feb 17, 2026Form 4 | LEIDEN JEFFREY MExecutive Chairman · DirectorAward · $0 · 8,269 sh |
| Feb 17, 2026Form 4 | WAGNER CHARLES F JREVP, CO & FOAward · $0 · 7,365 sh |
| Feb 17, 2026Form 4 | Sachdev AmitEVP Chief Patient & Ext Af OffAward · $0 · 5,789 sh |
| Feb 17, 2026Form 4 | Tatsis OuraniaEVP, Chief Reg. & Quality Off.Award · $0 · 5,789 sh · 10b5-1 |
| Feb 17, 2026Form 4 | Bozic CarmenEVP and CMOAward · $0 · 5,375 sh |
| Feb 17, 2026Form 4 | Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off.Award · $0 · 4,962 sh · 10b5-1 |
| Feb 17, 2026Form 4 | McKechnie DuncanEVP, Chief Commercial OfficerAward · $0 · 4,962 sh |
| Feb 17, 2026Form 4 | Biller JonathanEVP and Chief Legal OfficerAward · $0 · 4,135 sh · 10b5-1 |
| Feb 17, 2026Form 4 | Bunnage Mark E.EVP, Chief Scientific OfficerAward · $0 · 2,584 sh · 10b5-1 |
| Feb 17, 2026Form 4 | Ambrose KristenSVP & Chief Accounting OfficerAward · $0 · 1,809 sh · 10b5-1 |
| Feb 13, 2026Form 4 | Kewalramani ReshmaCEO & President · DirectorTax withholding · $6.4M · 13,041 sh |
| Feb 13, 2026Form 4 | WAGNER CHARLES F JREVP, CO & FOTax withholding · $2.2M · 4,565 sh |
| Feb 13, 2026Form 4 | Bozic CarmenEVP and CMOTax withholding · $1.9M · 3,804 sh |
| Feb 13, 2026Form 4 | Tatsis OuraniaEVP, Chief Reg. & Quality Off.Tax withholding · $1.9M · 3,804 sh · 10b5-1 |
| Feb 13, 2026Form 4 | Sachdev AmitEVP Chief Patient & Ext Af OffTax withholding · $1.7M · 3,548 sh |
| Feb 13, 2026Form 4 | Biller JonathanEVP and Chief Legal OfficerTax withholding · $1.5M · 2,993 sh · 10b5-1 |
| Feb 13, 2026Form 4 | Bunnage Mark E.EVP, Chief Scientific OfficerTax withholding · $1.1M · 2,283 sh |
| Feb 13, 2026Form 4 | McKechnie DuncanEVP, Chief Commercial OfficerTax withholding · $1.1M · 2,283 sh |
| Feb 13, 2026Form 4 | Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off.Tax withholding · $928K · 1,903 sh |
| Feb 13, 2026Form 4 | Ambrose KristenSVP & Chief Accounting OfficerTax withholding · $679K · 1,393 sh |
| Feb 10, 2026Form 4 | Kewalramani ReshmaCEO & President · DirectorTax withholding · $3.9M · 8,297 sh |
| Feb 10, 2026Form 4 | WAGNER CHARLES F JREVP, CO & FOTax withholding · $1.4M · 3,045 sh |
| Feb 10, 2026Form 4 | Bozic CarmenEVP and CMOTax withholding · $1.0M · 2,145 sh |
| Feb 10, 2026Form 4 | Tatsis OuraniaEVP, Chief Reg. & Quality Off.Tax withholding · $1.0M · 2,140 sh · 10b5-1 |
| Feb 10, 2026Form 4 | Sachdev AmitEVP Chief Patient & Ext Af OffTax withholding · $964K · 2,057 sh |
| Feb 10, 2026Form 4 | Biller JonathanEVP and Chief Legal OfficerTax withholding · $764K · 1,630 sh · 10b5-1 |
| Feb 10, 2026Form 4 | Bunnage Mark E.EVP, Chief Scientific OfficerTax withholding · $528K · 1,127 sh · 10b5-1 |
| Feb 10, 2026Form 4 | McKechnie DuncanEVP, Chief Commercial OfficerTax withholding · $528K · 1,127 sh |
| Feb 10, 2026Form 4 | Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off.Tax withholding · $408K · 872 sh · 10b5-1 |
| Feb 10, 2026Form 4 | Ambrose KristenSVP & Chief Accounting OfficerTax withholding · $277K · 592 sh · 10b5-1 |
| Jan 22, 2026Form 4 | Kewalramani ReshmaCEO & President · DirectorAward · $0 · 38,857 sh |
| Jan 22, 2026Form 4 | WAGNER CHARLES F JREVP, CO & FOAward · $0 · 13,600 sh |
| Jan 22, 2026Form 4 | Sachdev AmitEVP Chief Patient & Ext Af OffAward · $0 · 11,749 sh |
| Jan 22, 2026Form 4 | Tatsis OuraniaEVP, Chief Reg. & Quality Off.Award · $0 · 11,749 sh |
| Jan 22, 2026Form 4 | Bozic CarmenEVP and CMOAward · $0 · 11,333 sh |
| Jan 22, 2026Form 4 | ALTSHULER DAVIDEVP, Chief Scientific OfficerAward · $0 · 11,194 sh |
| Jan 22, 2026Form 4 | Biller JonathanEVP and Chief Legal OfficerAward · $0 · 9,068 sh |
| Jan 22, 2026Form 4 | LEIDEN JEFFREY MExecutive Chairman · DirectorAward · $0 · 9,012 sh |
| Jan 22, 2026Form 4 | Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off.Award · $0 · 7,817 sh |
| Jan 22, 2026Form 4 | McKechnie DuncanEVP, Chief Commercial OfficerAward · $0 · 6,800 sh |
| Jan 22, 2026Form 4 | Ambrose KristenSVP & Chief Accounting OfficerAward · $0 · 4,250 sh |
| Jan 15, 2026Form 4 | SACHS BRUCE IDirectorAward · Deferred Stock Units · $47K · 107.088 sh |
| Jan 15, 2026Form 4 | Upadhyay SuketuDirectorAward · Deferred Stock Units · $36K · 80.316 sh |
| Jan 6, 2026Form 4 | WAGNER CHARLES F JREVP, CO & FOExercise or conversion · $1.8M · 9,532 sh · 10b5-1 |
| Jan 6, 2026Form 4 | WAGNER CHARLES F JREVP, CO & FOExercise or conversion · Stock Option (Right to Buy) · $0 · 9,532 sh · 10b5-1 |
Reports and proxy statements#
Annual reports (10-K, 20-F, 40-F), quarterly reports (10-Q), current reports (8-K, 6-K) and proxy statements, newest first. An 8-K that furnishes a press release is headed by the release’s headline, its items beneath; any other 8-K is described by its items. A form opens the press release where there is one, else the document on EDGAR, or the filing’s index where it furnishes other exhibits.
2026 · 15 filings
| Filed | What it is |
|---|---|
| Sep 1, 20268-K | Directors or officers; compensation |
| Aug 4, 202610-Q | Quarterly report, Q2 2026 — revenue $3.33B (+12% y/y), net income $1.10B, EPS $4.31 |
| Aug 3, 20268-K | Earnings release — EPS $4.20 vs $4.15 est. (+1.2%); revenue $3.33B (+12% y/y) 1.7% |
| Jul 7, 20268-K | Material definitive agreement; Regulation FD disclosure; Other events |
| May 13, 20268-K | Directors or officers; compensation; Shareholder vote results |
| May 5, 202610-Q | Quarterly report, Q1 2026 — revenue $2.99B (+8% y/y), net income $1.03B, EPS $4.02 |
| May 4, 20268-K | Earnings release — EPS $3.95 vs $3.69 est. (+7.0%); revenue $2.99B (+8% y/y) 1.3% |
| Apr 29, 2026DEFA14A | Additional proxy materials |
| Apr 29, 20268-K | Directors or officers; compensation |
| Apr 2, 2026ARS | Annual report to shareholders |
| Apr 2, 2026DEFA14A | Additional proxy materials |
| Apr 2, 2026DEF 14A | Proxy statement |
| Mar 31, 20268-K | Other events |
| Feb 13, 202610-K | Annual report, FY2025 — revenue $12.00B (+9% y/y), net income $3.95B, EPS $15.32 |
| Feb 12, 20268-K | Earnings release — EPS $4.65 vs $4.40 est. (+5.7%); revenue $3.19B (+10% y/y) 5.7% |
2025 · 14 filings
| Filed | What it is |
|---|---|
| Nov 4, 202510-Q | Quarterly report, Q3 2025 — revenue $3.08B (+11% y/y), net income $1.08B, EPS $4.20 |
| Nov 3, 20258-K | Earnings release — EPS $4.22 vs $4.00 est. (+5.5%); revenue $3.08B (+11% y/y) 1.0% |
| Aug 5, 202510-Q | Quarterly report, Q2 2025 — revenue $2.96B (+12% y/y), net income $1.03B, EPS $3.99 |
| Aug 4, 20258-K | Results of operations; Directors or officers; compensation |
| May 19, 20258-K | Other events |
| May 14, 20258-K | Shareholder vote results |
| May 6, 202510-Q | Quarterly report, Q1 2025 — revenue $2.77B (+3% y/y), net income $646.3M, EPS $2.49 |
| May 5, 20258-K | Results of operations |
| Apr 3, 2025ARS | Annual report to shareholders |
| Apr 3, 2025DEFA14A | Additional proxy materials |
| Apr 3, 2025DEF 14A | Proxy statement |
| Mar 28, 20258-K | Other events |
| Feb 13, 202510-K | Annual report, FY2024 — revenue $11.02B (+12% y/y), net income −$535.6M, EPS −$2.08 |
| Feb 10, 20258-K | Results of operations; Directors or officers; compensation |
2024 · 18 filings
| Filed | What it is |
|---|---|
| Dec 20, 20248-K | Regulation FD disclosure |
| Nov 5, 202410-Q | Quarterly report, Q3 2024 — revenue $2.77B (+12% y/y), net income $1.05B, EPS $4.01 |
| Nov 4, 20248-K | Results of operations |
| Aug 16, 20248-K | Material definitive agreement |
| Aug 2, 202410-Q | Quarterly report, Q2 2024 — revenue $2.65B (+6% y/y), net income −$3.59B, EPS −$13.92 |
| Aug 1, 20248-K | Results of operations |
| Jun 27, 20248-K | Other events |
| May 20, 20248-K | Other events |
| May 15, 20248-K | Shareholder vote results |
| May 7, 202410-Q | Quarterly report, Q1 2024 — revenue $2.69B (+13% y/y), net income $1.10B, EPS $4.21 |
| May 6, 20248-K | Results of operations |
| Apr 16, 2024PX14A6G | Shareholder exempt solicitation |
| Apr 11, 20248-K | Material definitive agreement; Other events |
| Apr 4, 2024ARS | Annual report to shareholders |
| Apr 4, 2024DEFA14A | Additional proxy materials |
| Apr 4, 2024DEF 14A | Proxy statement |
| Feb 15, 202410-K | Annual report, FY2023 — revenue $9.87B (+11% y/y), net income $3.62B, EPS $13.89 |
| Feb 5, 20248-K | Results of operations |
2023 · 15 filings — 8 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
| Filed | What it is |
|---|---|
| Nov 7, 202310-Q | Quarterly report, Q3 2023 — revenue $2.48B (+6% y/y), net income $1.04B, EPS $3.97 |
| Aug 2, 202310-Q | Quarterly report, Q2 2023 — revenue $2.49B (+14% y/y), net income $915.7M, EPS $3.52 |
| May 2, 202310-Q | Quarterly report, Q1 2023 — revenue $2.37B (+13% y/y), net income $699.8M, EPS $2.69 |
| Apr 6, 2023ARS | Annual report to shareholders |
| Apr 6, 2023DEFA14A | Additional proxy materials |
| Apr 6, 2023DEF 14A | Proxy statement |
| Feb 10, 202310-K | Annual report, FY2022 — revenue $8.93B (+18% y/y), net income $3.32B, EPS $12.82 |
8 current reports (8-K) not listed; the year is on EDGAR.
2022 · 14 filings — 8 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
| Filed | What it is |
|---|---|
| Oct 28, 202210-Q | Quarterly report, Q3 2022 — revenue $2.33B (+18% y/y), net income $930.5M, EPS $3.59 |
| Aug 5, 202210-Q | Quarterly report, Q2 2022 — revenue $2.20B (+22% y/y), net income $810.5M, EPS $3.13 |
| May 6, 202210-Q | Quarterly report, Q1 2022 — revenue $2.10B (+22% y/y), net income $762.1M, EPS $2.96 |
| Apr 7, 2022DEFA14A | Additional proxy materials |
| Apr 7, 2022DEF 14A | Proxy statement |
| Feb 9, 202210-K | Annual report, FY2021 — revenue $7.57B (+22% y/y), net income $2.34B, EPS $9.01 |
8 current reports (8-K) not listed; the year is on EDGAR.
2021 · 14 filings — 7 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
| Filed | What it is |
|---|---|
| Nov 3, 202110-Q | Quarterly report, Q3 2021 — revenue $1.98B (+29% y/y), net income $851.9M, EPS $3.28 |
| Jul 30, 202110-Q | Quarterly report, Q2 2021 — revenue $1.79B (+18% y/y), net income $67.0M, EPS $0.26 |
| Apr 30, 202110-Q | Quarterly report, Q1 2021 — revenue $1.72B (+14% y/y), net income $653.1M, EPS $2.49 |
| Apr 29, 2021PX14A6G | Shareholder exempt solicitation |
| Apr 8, 2021DEFA14A | Additional proxy materials |
| Apr 8, 2021DEF 14A | Proxy statement |
| Feb 11, 202110-K | Annual report, FY2020 — revenue $6.21B (+49% y/y), net income $2.71B, EPS $10.29 |
7 current reports (8-K) not listed; the year is on EDGAR.
2020 · 16 filings — 8 × 8-K, 3 × 10-Q, 2 × DEFA14A and 3 other forms
| Filed | What it is |
|---|---|
| Oct 30, 202010-Q | Quarterly report, Q3 2020 — revenue $1.54B (+62% y/y), net income $667.4M, EPS $2.53 |
| Jul 31, 202010-Q | Quarterly report, Q2 2020 — revenue $1.52B (+62% y/y), net income $837.3M, EPS $3.18 |
| Jun 2, 2020PX14A6G | Shareholder exempt solicitation |
| May 1, 202010-Q | Quarterly report, Q1 2020 — revenue $1.52B (+76% y/y), net income $602.8M, EPS $2.29 |
| Apr 28, 2020DEFA14A | Additional proxy materials |
| Apr 28, 2020DEFA14A | Additional proxy materials |
| Apr 28, 2020DEF 14A | Proxy statement |
| Feb 13, 202010-K | Annual report, FY2019 — revenue $4.16B (+37% y/y), net income $1.18B, EPS $4.51 |
8 current reports (8-K) not listed; the year is on EDGAR.
2019 · 21 filings — 14 × 8-K, 3 × 10-Q, 2 × PX14A6G and 2 other forms
| Filed | What it is |
|---|---|
| Oct 31, 201910-Q | Quarterly report, Q3 2019 — revenue $949.8M (+21% y/y), net income $57.5M, EPS $0.22 |
| Aug 1, 201910-Q | Quarterly report, Q2 2019 — revenue $941.3M (+25% y/y), net income $267.4M, EPS $1.03 |
| May 21, 2019PX14A6G | Shareholder exempt solicitation |
| May 6, 2019PX14A6G | Shareholder exempt solicitation |
| May 1, 201910-Q | Quarterly report, Q1 2019 — revenue $858.4M (+34% y/y), net income $268.6M, EPS $1.03 |
| Apr 26, 2019DEF 14A | Proxy statement |
| Feb 13, 201910-K | Annual report, FY2018 — revenue $3.05B (+22% y/y), net income $2.10B, EPS $8.09 |
14 current reports (8-K) not listed; the year is on EDGAR.
2018 · 14 filings — 7 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
| Filed | What it is |
|---|---|
| Oct 25, 201810-Q | Quarterly report, Q3 2018 — revenue $784.5M (+36% y/y), net income $128.7M, EPS $0.50 |
| Jul 26, 201810-Q | Quarterly report, Q2 2018 — revenue $752.2M (+38% y/y), net income $207.4M, EPS $0.80 |
| May 7, 2018PX14A6G | Shareholder exempt solicitation |
| Apr 27, 201810-Q | Quarterly report, Q1 2018 — revenue $640.8M (−10% y/y), net income $210.3M, EPS $0.81 |
| Apr 17, 2018DEF 14A | Proxy statement |
| Apr 6, 2018PRE 14A | Preliminary proxy statement |
| Feb 15, 201810-K | Annual report, FY2017 — revenue $2.49B (+46% y/y), net income $263.5M, EPS $1.04 |
7 current reports (8-K) not listed; the year is on EDGAR.
2017 · 22 filings — 11 × 8-K, 3 × 10-Q, 2 × 8-K/A and 5 other forms
| Filed | What it is |
|---|---|
| Oct 30, 201710-Q | Quarterly report, Q3 2017 — revenue $578.2M (+40% y/y), net income −$103.0M, EPS −$0.41 |
| Jul 28, 201710-Q | Quarterly report, Q2 2017 — revenue $544.1M (+26% y/y), net income $18.0M, EPS $0.07 |
| May 22, 2017DEFA14A | Additional proxy materials |
| May 16, 2017PX14A6G | Shareholder exempt solicitation |
| Apr 28, 201710-Q | Quarterly report, Q1 2017 — revenue $714.7M (+80% y/y), net income $247.8M, EPS $0.99 |
| Apr 28, 2017DEF 14A | Proxy statement |
| Apr 17, 2017PRE 14A | Preliminary proxy statement |
| Mar 6, 2017DEFA14A | Additional proxy materials |
| Feb 23, 201710-K | Annual report, FY2016 — revenue $1.70B (+65% y/y), net income −$112.1M, EPS −$0.46 |
13 current reports (8-K) not listed; the year is on EDGAR.
2016 · 14 filings — 9 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
Counted, not listed; the year is on EDGAR.
2015 · 21 filings — 12 × 8-K, 3 × 10-Q, 2 × PX14A6G and 4 other forms
Counted, not listed; the year is on EDGAR.
2014 · 20 filings — 12 × 8-K, 3 × 10-Q, 1 × 10-K and 4 other forms
Counted, not listed; the year is on EDGAR.
2013 · 14 filings — 8 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
Counted, not listed; the year is on EDGAR.
2012 · 17 filings — 9 × 8-K, 3 × 10-Q, 2 × 10-Q/A and 3 other forms
Counted, not listed; the year is on EDGAR.
2011 · 23 filings — 16 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
Counted, not listed; the year is on EDGAR.
2010 · 19 filings — 13 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
Counted, not listed; the year is on EDGAR.
2009 · 24 filings — 17 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
Counted, not listed; the year is on EDGAR.
2008 · 20 filings — 13 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
Counted, not listed; the year is on EDGAR.
2007 · 17 filings — 11 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
Counted, not listed; the year is on EDGAR.
2006 · 22 filings — 16 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
Counted, not listed; the year is on EDGAR.
2005 · 27 filings — 21 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
Counted, not listed; the year is on EDGAR.
2004 · 23 filings — 14 × 8-K, 3 × 10-Q, 2 × 8-K/A and 4 other forms
Counted, not listed; the year is on EDGAR.
2003 · 16 filings — 11 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
Counted, not listed; the year is on EDGAR.
2002 · 9 filings — 3 × 10-Q, 3 × 8-K, 1 × 10-K and 2 other forms
Counted, not listed; the year is on EDGAR.
2001 · 11 filings — 3 × 10-Q, 3 × 8-K, 1 × 10-K and 4 other forms
Counted, not listed; the year is on EDGAR.
2000 · 13 filings — 8 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
Counted, not listed; the year is on EDGAR.
1999 · 5 filings — 3 × 10-Q, 1 × 10-K, 1 × DEF 14A
Counted, not listed; the year is on EDGAR.
1998 · 5 filings — 3 × 10-Q, 1 × 10-K405, 1 × DEF 14A
Counted, not listed; the year is on EDGAR.
1997 · 7 filings — 3 × 10-Q, 1 × 10-K405, 1 × 8-K and 2 other forms
Counted, not listed; the year is on EDGAR.
1996 · 5 filings — 3 × 10-Q, 2 × 10-Q/A
Counted, not listed; the year is on EDGAR.
Insider, ownership and other filings#
Insider ownership (Forms 3, 4, 5 and 144), beneficial ownership (Schedules 13D and 13G), registration and prospectus (S-1, S-3, S-8, 424B and related) and the rest, counted by year, with the newest 25 of each of the latest 3 years shown. A Form 4 is one insider’s transaction report; a 13G is a passive holder above five percent.
2026 · 167 filings — 100 × 4, 48 × 144, 7 × S-8 POS and 6 other forms
| Filed | What it is |
|---|---|
| Sep 10, 20264 | Insider transaction (Form 4) |
| Sep 10, 20263 | Initial insider holdings (Form 3) |
| Sep 1, 20264 | Insider transaction (Form 4) |
| Aug 31, 20264 | Insider transaction (Form 4) |
| Aug 27, 2026144 | Notice of proposed sale (Form 144) |
| Jul 23, 20264 | Insider transaction (Form 4) |
| Jul 23, 20264 | Insider transaction (Form 4) |
| Jul 17, 20264 | Insider transaction (Form 4) |
| Jul 17, 20264 | Insider transaction (Form 4) |
| Jul 7, 20264 | Insider transaction (Form 4) |
| Jul 7, 20264 | Insider transaction (Form 4) |
| Jul 6, 20264 | Insider transaction (Form 4) |
| Jul 2, 2026144 | Notice of proposed sale (Form 144) |
| Jul 2, 2026144 | Notice of proposed sale (Form 144) |
| Jul 1, 2026144 | Notice of proposed sale (Form 144) |
| Jun 30, 20264 | Insider transaction (Form 4) |
| Jun 26, 2026144 | Notice of proposed sale (Form 144) |
| Jun 23, 20264 | Insider transaction (Form 4) |
| Jun 18, 2026144 | Notice of proposed sale (Form 144) |
| Jun 17, 20264 | Insider transaction (Form 4) |
| Jun 15, 2026144 | Notice of proposed sale (Form 144) |
| Jun 9, 20264 | Insider transaction (Form 4) |
| Jun 5, 2026144 | Notice of proposed sale (Form 144) |
| Jun 3, 20264 | Insider transaction (Form 4) |
| Jun 2, 20264 | Insider transaction (Form 4) |
The newest 25 of 167 shown; the full year is on EDGAR.
2025 · 139 filings — 98 × 4, 33 × 144, 2 × SCHEDULE 13G/A and 5 other forms
| Filed | What it is |
|---|---|
| Dec 5, 20254 | Insider transaction (Form 4) |
| Dec 5, 20254 | Insider transaction (Form 4) |
| Dec 5, 20254 | Insider transaction (Form 4) |
| Dec 5, 20254 | Insider transaction (Form 4) |
| Dec 3, 2025144 | Notice of proposed sale (Form 144) |
| Dec 3, 2025144 | Notice of proposed sale (Form 144) |
| Dec 3, 2025144 | Notice of proposed sale (Form 144) |
| Dec 3, 2025144 | Notice of proposed sale (Form 144) |
| Dec 3, 2025144 | Notice of proposed sale (Form 144) |
| Nov 20, 20254 | Insider transaction (Form 4) |
| Nov 20, 2025144 | Notice of proposed sale (Form 144) |
| Nov 19, 20254 | Insider transaction (Form 4) |
| Nov 17, 20254 | Insider transaction (Form 4) |
| Nov 17, 2025144 | Notice of proposed sale (Form 144) |
| Nov 14, 2025144 | Notice of proposed sale (Form 144) |
| Nov 13, 2025144 | Notice of proposed sale (Form 144) |
| Oct 17, 20254 | Insider transaction (Form 4) |
| Oct 17, 20254 | Insider transaction (Form 4) |
| Oct 3, 20254 | Insider transaction (Form 4) |
| Oct 2, 2025144 | Notice of proposed sale (Form 144) |
| Aug 29, 20254 | Insider transaction (Form 4) |
| Aug 27, 2025144 | Notice of proposed sale (Form 144) |
| Aug 7, 20254 | Insider transaction (Form 4) |
| Aug 7, 20254 | Insider transaction (Form 4) |
| Jul 17, 20254 | Insider transaction (Form 4) |
The newest 25 of 139 shown; the full year is on EDGAR.
2024 · 167 filings — 94 × 4, 60 × 144, 4 × SC 13G/A and 5 other forms
| Filed | What it is |
|---|---|
| Nov 19, 20244 | Insider transaction (Form 4) |
| Nov 15, 2024144 | Notice of proposed sale (Form 144) |
| Nov 13, 20244 | Insider transaction (Form 4) |
| Nov 12, 20244 | Insider transaction (Form 4) |
| Nov 12, 2024144 | Notice of proposed sale (Form 144) |
| Nov 8, 2024144 | Notice of proposed sale (Form 144) |
| Oct 17, 20244 | Insider transaction (Form 4) |
| Oct 3, 20244 | Insider transaction (Form 4) |
| Oct 2, 2024144 | Notice of proposed sale (Form 144) |
| Sep 4, 20244 | Insider transaction (Form 4) |
| Sep 4, 20244 | Insider transaction (Form 4) |
| Aug 30, 2024144 | Notice of proposed sale (Form 144) |
| Aug 30, 2024144 | Notice of proposed sale (Form 144) |
| Aug 12, 20244 | Insider transaction (Form 4) |
| Aug 8, 20244 | Insider transaction (Form 4) |
| Aug 8, 2024144 | Notice of proposed sale (Form 144) |
| Aug 7, 2024144 | Notice of proposed sale (Form 144) |
| Aug 2, 20244 | Insider transaction (Form 4) |
| Aug 1, 20244 | Insider transaction (Form 4) |
| Aug 1, 2024144 | Notice of proposed sale (Form 144) |
| Jul 30, 2024144 | Notice of proposed sale (Form 144) |
| Jul 25, 20244 | Insider transaction (Form 4) |
| Jul 24, 20244 | Insider transaction (Form 4) |
| Jul 24, 2024144 | Notice of proposed sale (Form 144) |
| Jul 22, 2024144 | Notice of proposed sale (Form 144) |
The newest 25 of 167 shown; the full year is on EDGAR.
2023 · 170 filings — 115 × 4, 47 × 144, 3 × 3 and 3 other forms
Counted, not listed; the year is on EDGAR.
2022 · 125 filings — 113 × 4, 4 × SC 13G/A, 2 × 3 and 5 other forms
Counted, not listed; the year is on EDGAR.
2021 · 91 filings — 84 × 4, 4 × SC 13G/A, 3 × 3
Counted, not listed; the year is on EDGAR.
2020 · 139 filings — 130 × 4, 4 × SC 13G/A, 2 × SEC STAFF LETTER and 3 other forms
Counted, not listed; the year is on EDGAR.
2019 · 119 filings — 107 × 4, 4 × 3, 4 × SC 13G/A and 3 other forms
Counted, not listed; the year is on EDGAR.
2018 · 127 filings — 116 × 4, 6 × SC 13G/A, 1 × 3 and 4 other forms
Counted, not listed; the year is on EDGAR.
2017 · 119 filings — 100 × 4, 8 × SC 13G/A, 3 × CT ORDER and 7 other forms
Counted, not listed; the year is on EDGAR.
2016 · 109 filings — 86 × 4, 8 × SC 13G/A, 6 × CORRESP and 6 other forms
Counted, not listed; the year is on EDGAR.
2015 · 160 filings — 143 × 4, 6 × SC 13G/A, 2 × 5 and 7 other forms
Counted, not listed; the year is on EDGAR.
2014 · 140 filings — 128 × 4, 4 × SC 13G/A, 3 × CT ORDER and 3 other forms
Counted, not listed; the year is on EDGAR.
2013 · 130 filings — 117 × 4, 6 × SC 13G/A, 2 × UPLOAD and 5 other forms
Counted, not listed; the year is on EDGAR.
2012 · 140 filings — 109 × 4, 6 × CT ORDER, 6 × SC 13G/A and 7 other forms
Counted, not listed; the year is on EDGAR.
2011 · 134 filings — 119 × 4, 5 × SC 13G/A, 3 × 3 and 3 other forms
Counted, not listed; the year is on EDGAR.
2010 · 78 filings — 57 × 4, 5 × SC 13G/A, 3 × SC 13G and 8 other forms
Counted, not listed; the year is on EDGAR.
2009 · 126 filings — 99 × 4, 5 × 424B5, 5 × CORRESP and 9 other forms
Counted, not listed; the year is on EDGAR.
2008 · 121 filings — 92 × 4, 4 × SC 13G/A, 3 × CORRESP and 11 other forms
Counted, not listed; the year is on EDGAR.
2007 · 129 filings — 116 × 4, 7 × SC 13G/A, 3 × 3 and 2 other forms
Counted, not listed; the year is on EDGAR.
2006 · 140 filings — 121 × 4, 5 × SC 13G/A, 2 × 424B5 and 8 other forms
Counted, not listed; the year is on EDGAR.
2005 · 104 filings — 70 × 4, 14 × 424B3, 3 × 3 and 9 other forms
Counted, not listed; the year is on EDGAR.
2004 · 132 filings — 117 × 4, 4 × 3, 2 × S-3 and 8 other forms
Counted, not listed; the year is on EDGAR.
2003 · 63 filings — 56 × 4, 4 × SC 13G/A, 2 × 3 and 1 other form
Counted, not listed; the year is on EDGAR.
2002 · 5 filings — 3 × SC 13G/A, 1 × 424B3, 1 × SC 13G
Counted, not listed; the year is on EDGAR.
2001 · 25 filings — 10 × 425, 5 × 424B3, 3 × SC 13G/A and 5 other forms
Counted, not listed; the year is on EDGAR.
2000 · 13 filings — 6 × 424B3, 3 × SC 13G/A, 2 × S-3 and 1 other form
Counted, not listed; the year is on EDGAR.
1999 · 7 filings — 4 × SC 13G/A, 2 × SC 13G, 1 × S-8
Counted, not listed; the year is on EDGAR.
1998 · 6 filings — 3 × SC 13G/A, 2 × SC 13G, 1 × S-8
Counted, not listed; the year is on EDGAR.
1997 · 7 filings — 1 × 424B1, 1 × S-3, 1 × S-3/A and 4 other forms
Counted, not listed; the year is on EDGAR.
1996 · 6 filings — 1 × 10-C, 1 × 424B1, 1 × S-3 and 3 other forms
Counted, not listed; the year is on EDGAR.
1995 · 1 filing — 1 × SC 13G/A
Counted, not listed; the year is on EDGAR.
About this data#
Vertex Pharmaceuticals Incorporated (VRTX) has 3,634 filings on EDGAR going back to 1995: 31 annual reports, 98 quarterly reports and 293 current reports, plus proxy statements, insider forms and ownership schedules. Its latest annual report, a 10-K, was filed on Feb 13, 2026 for the fiscal year ended Dec 31, 2025. The most recent 8-K, on Sep 1, 2026, covered directors or officers; compensation. Over the last 13 months insiders sold $87.5M in 51 sales and bought nothing on the open market; 100 other transactions (awards, exercises, tax withholding, gifts and plan purchases). Not investment advice.
Every row is a filing EDGAR lists for the registrants that have been Vertex Pharmaceuticals Incorporated, read from the SEC’s submissions index each morning; a filing accepted after that read appears the next day. Where a company changed its filing entity (a holding-company reorganisation, Google into Alphabet) the predecessor’s filings are shown for the years it filed as the company, derived from the filings themselves. Dates are the filing date; the period is the report’s own. The latest 3 years of reports are listed in full, the next years to 10 without their 8-Ks, and older years are counted; the other forms are counted too, with the newest 25 of each of the latest 3 years shown. Insider transactions are the Form 4 and Form 5 documents themselves, filed since January 2026, every number as the insider filed it: a day’s lots are summed, a blank price adds its shares and no dollars, and a purchase through an employee stock plan is a plan purchase, not insider buying. An 8-K’s headline is the first line of the press release it furnishes (Exhibit 99), read from the filing and shown word for word; where two independent readings of the exhibit do not agree, the 8-K is described by its items instead. The documents stay on sec.gov, public domain, and every link opens the SEC’s copy. ChartRow does not summarise or interpret filings.
FAQ#
- Where can I read VRTX's latest 10-K?
- VRTX's latest annual report, a 10-K, was filed on Feb 13, 2026 for the fiscal year ended Dec 31, 2025. It is linked above and opens on EDGAR, the SEC's own site, where every exhibit is also listed.
- When did VRTX last file an 8-K?
- On Sep 1, 2026 it covered directors or officers; compensation. An 8-K reports a material event between quarterly reports; the one that furnishes the quarter's results is filed under Item 2.02, last on Aug 3, 2026.
- Are VRTX insiders buying or selling?
- Over the last 13 months insiders sold $87.5M in 51 sales and bought nothing on the open market; 100 other transactions (awards, exercises, tax withholding, gifts and plan purchases). The most recent sale: McKechnie Duncan (EVP, Chief Commercial Officer) sold 1,541 shares on Jul 2, 2026 for $800K, under a 10b5-1 plan. Every figure is as the insider filed it on Form 4; a sale under a 10b5-1 plan was scheduled in advance.
- How many SEC filings has VRTX made?
- 3,634 filings are on EDGAR under the registrant records that have been Vertex Pharmaceuticals Incorporated, going back to 1995; 2,745 of them are insider ownership forms (Forms 3, 4, 5 and 144).